New research partnership to look at new treatments for diabetic eye disease
JDRF will offer up to USD2.2 million in overall support and research expertise to KalVista to help advance its plasma kallikrein inhibitor for clinical trials, as well as to achieve data on its potential for treating diabetic macular edema (DME). DME involves swelling in the retina that impairs vision, and can happen at any time during diabetic retinopathy.
Plasma kallikrein is a potential therapeutic target for patients with DME, as its activation raises the inflammation and permeability of blood vessels by producing bradykinin, a hormone that causes blood vessels to dilate or enlarge. Plasma kallikrein inhibitors are therefore thought to lower retinal vessel leakage as they are able to suppress excessive production of bradykinin.
Aaron Kowalski, assistant vice president of treatment therapies for JDRF, commented "What makes our collaboration with KalVista so exciting is that we are gradually seeing this novel therapy, which could represent a whole new approach to treating DME, move from basic research discovery into a potential commercially viable drug with the help of JDRF funding."
Also related to this storyHealthcare Professionals
Join the Community
Diabetes Book Reviews
Blood Glucose Monitoring System
Type 1 Diabetes
Clinical Trials and Diabetes
Prevention of Diabetes
Health watchdog rejects use of eye drug Lucentis for diabetics
Charity seeking feedback on diabetes eye screening information
New film reminds diabetics about importance of eye check-ups
Eye implant could benefit diabetes patients
Eye test could help detect diabetic nerve damage
Poor sleep patterns raise eye disease risk for diabetics
Eye disorder more common in older US adults with diabetes
Diabetic eye disease helped by new therapies
Eye disease reduced by controlling blood sugar in diabetics
Diabetes eye problems could be detected by computers
Roche eye drug could treat diabetes retinopathy